فوق تحت
عضو نشط
وهو أيضا شرعي بفلتر الأخ هاني
Buy Opinion: 1.00 - 1.20
Short-term Sell: 1.50 - 2.30
Long-term Sell: 3.20 - 3.75
أحب لأخيك ماتحب لنفسك
أخوكم أبو محمد
ABMC Nasdaq American Bio Medica Corp.
800.227.1243 Americabiomedica.com Shares Outstanding: 20,640,000
The following report and company descriptions are presented on this page as originally published and will not be updated. Therefore some time-sensitive data may no longer be accurate. Be sure to consult our Hot List to get our original opinions on buy and sell price ranges.
October 7, 2003.
Highlights
ABMC develops some of the most effective on-site tests for detecting substance abuse
In July, the company reported their sixth consecutive quarter of growth
They also reported a net income increase of 68%, and net sales increase of 20%
ABMC manufacturers the only FDA approved on-site test for oxycodone
The company was recently named to Deloitte & Touche Technology Fast 500
Outlook- American Bio Media Corp. (ABMC) is an industry leading advanced medical supplies company that can help companies detect substance abuse. ABMC has cutting edge technology, surging revenues, an expanding product line, and distribution base and is committed to bringing long-term growth and success to its company…and shareholders.
Currently, 2/3 of drug abusers in America are employed, and almost 10% use drugs in the workplace. Collectively, substance abusers have an absentee rate of 30-35 days per year and cost U.S. businesses over $100 billion per year.
ABMC’s proprietary technology and broad acceptance can help prevent drug abuse, enhance safety, improve worksite productivity, and save money.
Additionally, the company’s innovative drug tests can provide accurate results at a fraction of the cost of larger, more expensive systems.
Business Profile - ABMC develops, manufactures and markets inexpensive immunoassay diagnostic test kits, primarily for the immediate, onsite screening for illicit drugs, including: THC, PCP, cocaine, opiates, amphetamines, ecstasy and oxycodone.
The company's drug abuse screening products offer healthcare, law enforcement, government, industrial safety, and educational professionals, self-contained, one-step screening devices capable of identifying illicit drug use within minutes.
ABMC’s patented technology includes: Rapid Drug Screen, Rapid One, and Rapid Tec - for the presence or absence of drugs of abuse in urine; while OralStat6 tests for the presence or absence of drugs of abuse in saliva.
ABMC currently has 20 distributors representing 29 countries outside the United States.
Fundamental Analysis - On July 21, 2003 ABMC announced their fiscal results for the three and six months ended June 30, 2003.
Net sales for the second quarter of 2003 were $3,171,000; ABMC’s highest quarterly net sales reported to date, and the sixth consecutive quarter of sequential growth. The second quarter net sales represent an increase of 17% over the same period last year, and an increase of 20% over the preceding quarter. For the six months ended June 30, 2003, net sales rose 17% to $5,820,000.
Net income for the second quarter rose 68% to $424,000, compared to $252,000 for the same three month period last year. For the first six months of 2003, ABMC reported net income of $417,000, compared to $306,000 for the same period a year ago.
Commenting on the financial results, ABMC Chairman and CEO Gerald A. Moore stated, "Our consecutive improvement in net sales year over year and the record sales in the second quarter reflect the company's continued penetration into our core markets especially in sales to national and state government accounts."
"We remain committed to bringing long-term growth
and success to the Company and its shareholders."
Recent News - On June 19 ABMC announced that it has signed a global agreement with ChemProbe, Inc. that will allow ABMC to exclusively market alcohol test strips in specific markets and market adulterant detection strips developed by ChemProbe.
Through this agreement, ABMC hopes to further bolster its portfolio of substance abuse testing products in order to meet the increasingly specialized needs of various markets. The agreement will allow ABMC to market these strips to criminal justice, workplace, and health care markets on a global basis.
"We are aggressively expanding our capabilities in terms of the products we offer customers, both through development of our own proprietary technologies, and partnerships with companies that have already created viable solutions," said Gerald A. Moore, Chairman and CEO of ABMC. "In this case, ChemProbe has created two very functional testing technologies that offer immediate market potential."
On June 18, the company announced that a comprehensive comparison of opiate test results conducted at UCLA, from four testing systems, showed that ABMC’s Rapid One Oxy examine was the only test that demonstrated 100% reliability for returning positive results for oxycodone, a commonly-abused prescription pain medicine.
According to ABMC Chairman and CEO Gerald A. Moore, the results are significant because Rapid One Oxy is an on-site diagnostic assay, and the other three systems are expensive, laboratory instruments, typically based in a clinical setting.
"The study showed that the laboratory-based drugs of abuse screening methods fail to consistently pick up oxycodone as reliably as Rapid One Oxy," said Moore. "These independent results are a tremendous justification of Rapid One Oxy as the leading diagnostic assay for detecting oxycodone, not only in terms of cost and convenience, but in terms of straight performance. We simply beat more expensive, larger systems with an on-site test."
Rapid One Oxy is currently the only FDA-cleared on-site assay
specifically for oxycodone detection.
And, on June 2 ABMC announced that it has received clearance from the United States Food and Drug Administration (FDA) for new tests in its Rapid Tec product series that include assays for methamphetamines and opiates at a 300 ng cutoff level.
The company also launched Rapid Tec 5, which tests for THC, cocaine, amphetamines, benzodiazepines, and opiates, for forensic use.
These FDA clearances are the latest in a string of new product approvals for ABMC, which is broadening its technological base to offer more specific and flexible drug testing solutions to meet customer needs.
Conclusion - An industry leading advanced medical supplies company, ABMC’s proprietary technology can help companies prevent drug abuse, enhance safety, increase worksite productivity, save money and ultimately save lives.
A financially solid company with surging revenues, an expanding product line and distribution base, and recent FDA approvals, ABMC is committed to bringing long-term growth and success to its company…and shareholders.
Part of achieving this success will depend on the products that ABMC provides and on the further strengthening of their market position. The company hopes to achieve this through ongoing R&D and marketing initiatives.
While ABMC is currently trading for $1.16, the addition of new products and licensing agreements coupled with speculation on its upcoming quarterly report could help the company’s share price ramp upward. And that could help members of PeterLeeds.com add significant gains to their portfolios.
--------------------------------------------------------------------------------
Buy Opinion: 1.00 - 1.20
Short-term Sell: 1.50 - 2.30
Long-term Sell: 3.20 - 3.75
أحب لأخيك ماتحب لنفسك
أخوكم أبو محمد
ABMC Nasdaq American Bio Medica Corp.
800.227.1243 Americabiomedica.com Shares Outstanding: 20,640,000
The following report and company descriptions are presented on this page as originally published and will not be updated. Therefore some time-sensitive data may no longer be accurate. Be sure to consult our Hot List to get our original opinions on buy and sell price ranges.
October 7, 2003.
Highlights
ABMC develops some of the most effective on-site tests for detecting substance abuse
In July, the company reported their sixth consecutive quarter of growth
They also reported a net income increase of 68%, and net sales increase of 20%
ABMC manufacturers the only FDA approved on-site test for oxycodone
The company was recently named to Deloitte & Touche Technology Fast 500
Outlook- American Bio Media Corp. (ABMC) is an industry leading advanced medical supplies company that can help companies detect substance abuse. ABMC has cutting edge technology, surging revenues, an expanding product line, and distribution base and is committed to bringing long-term growth and success to its company…and shareholders.
Currently, 2/3 of drug abusers in America are employed, and almost 10% use drugs in the workplace. Collectively, substance abusers have an absentee rate of 30-35 days per year and cost U.S. businesses over $100 billion per year.
ABMC’s proprietary technology and broad acceptance can help prevent drug abuse, enhance safety, improve worksite productivity, and save money.
Additionally, the company’s innovative drug tests can provide accurate results at a fraction of the cost of larger, more expensive systems.
Business Profile - ABMC develops, manufactures and markets inexpensive immunoassay diagnostic test kits, primarily for the immediate, onsite screening for illicit drugs, including: THC, PCP, cocaine, opiates, amphetamines, ecstasy and oxycodone.
The company's drug abuse screening products offer healthcare, law enforcement, government, industrial safety, and educational professionals, self-contained, one-step screening devices capable of identifying illicit drug use within minutes.
ABMC’s patented technology includes: Rapid Drug Screen, Rapid One, and Rapid Tec - for the presence or absence of drugs of abuse in urine; while OralStat6 tests for the presence or absence of drugs of abuse in saliva.
ABMC currently has 20 distributors representing 29 countries outside the United States.
Fundamental Analysis - On July 21, 2003 ABMC announced their fiscal results for the three and six months ended June 30, 2003.
Net sales for the second quarter of 2003 were $3,171,000; ABMC’s highest quarterly net sales reported to date, and the sixth consecutive quarter of sequential growth. The second quarter net sales represent an increase of 17% over the same period last year, and an increase of 20% over the preceding quarter. For the six months ended June 30, 2003, net sales rose 17% to $5,820,000.
Net income for the second quarter rose 68% to $424,000, compared to $252,000 for the same three month period last year. For the first six months of 2003, ABMC reported net income of $417,000, compared to $306,000 for the same period a year ago.
Commenting on the financial results, ABMC Chairman and CEO Gerald A. Moore stated, "Our consecutive improvement in net sales year over year and the record sales in the second quarter reflect the company's continued penetration into our core markets especially in sales to national and state government accounts."
"We remain committed to bringing long-term growth
and success to the Company and its shareholders."
Recent News - On June 19 ABMC announced that it has signed a global agreement with ChemProbe, Inc. that will allow ABMC to exclusively market alcohol test strips in specific markets and market adulterant detection strips developed by ChemProbe.
Through this agreement, ABMC hopes to further bolster its portfolio of substance abuse testing products in order to meet the increasingly specialized needs of various markets. The agreement will allow ABMC to market these strips to criminal justice, workplace, and health care markets on a global basis.
"We are aggressively expanding our capabilities in terms of the products we offer customers, both through development of our own proprietary technologies, and partnerships with companies that have already created viable solutions," said Gerald A. Moore, Chairman and CEO of ABMC. "In this case, ChemProbe has created two very functional testing technologies that offer immediate market potential."
On June 18, the company announced that a comprehensive comparison of opiate test results conducted at UCLA, from four testing systems, showed that ABMC’s Rapid One Oxy examine was the only test that demonstrated 100% reliability for returning positive results for oxycodone, a commonly-abused prescription pain medicine.
According to ABMC Chairman and CEO Gerald A. Moore, the results are significant because Rapid One Oxy is an on-site diagnostic assay, and the other three systems are expensive, laboratory instruments, typically based in a clinical setting.
"The study showed that the laboratory-based drugs of abuse screening methods fail to consistently pick up oxycodone as reliably as Rapid One Oxy," said Moore. "These independent results are a tremendous justification of Rapid One Oxy as the leading diagnostic assay for detecting oxycodone, not only in terms of cost and convenience, but in terms of straight performance. We simply beat more expensive, larger systems with an on-site test."
Rapid One Oxy is currently the only FDA-cleared on-site assay
specifically for oxycodone detection.
And, on June 2 ABMC announced that it has received clearance from the United States Food and Drug Administration (FDA) for new tests in its Rapid Tec product series that include assays for methamphetamines and opiates at a 300 ng cutoff level.
The company also launched Rapid Tec 5, which tests for THC, cocaine, amphetamines, benzodiazepines, and opiates, for forensic use.
These FDA clearances are the latest in a string of new product approvals for ABMC, which is broadening its technological base to offer more specific and flexible drug testing solutions to meet customer needs.
Conclusion - An industry leading advanced medical supplies company, ABMC’s proprietary technology can help companies prevent drug abuse, enhance safety, increase worksite productivity, save money and ultimately save lives.
A financially solid company with surging revenues, an expanding product line and distribution base, and recent FDA approvals, ABMC is committed to bringing long-term growth and success to its company…and shareholders.
Part of achieving this success will depend on the products that ABMC provides and on the further strengthening of their market position. The company hopes to achieve this through ongoing R&D and marketing initiatives.
While ABMC is currently trading for $1.16, the addition of new products and licensing agreements coupled with speculation on its upcoming quarterly report could help the company’s share price ramp upward. And that could help members of PeterLeeds.com add significant gains to their portfolios.
--------------------------------------------------------------------------------
